Management of hepatitis C infection after liver transplantation

Drugs

Volumn 67, Issue 6, 2007, Pages 871-885

  Alsatie, Mazen ^a   Chalasani, Naga ^a   Kwo, Paul Y ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; INTERFERON; INTERLEUKIN 2; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2B; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ANEMIA; BILIARY TRACT DISEASE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROSIS; GRAFT FAILURE; GRAFT INFECTION; GRAFT REJECTION; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; POSTOPERATIVE COMPLICATION; RECURRENT INFECTION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

HEPATITIS C VIRUS;

EID: 34247266730     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767060-00004     Document Type: Review

References (116)

1. Belle SH, Beringer KC, Detre KM. Recent findings concerning liver transplantation in the United States. Clin Transpl 1996:15-29
2. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 Apr; 122 (4): 889-96
3. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001 Sep; 7 (9): 790-6
4. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001 Nov; 35 (5): 666-78
5. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998 Sep; 28 (3): 823-30
6. Fukumoto T, Berg T, Ku Y, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996 Dec; 24 (6): 1351-4
7. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996 Mar 28; 334 (13): 815-20
8. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996 Jan; 110 (1): 167-77
9. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999 Jan; 29 (1): 250-6
10. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the longterm viability of the graft. Transplantation 2002 Jan 15; 73 (1): 56-63
11. Bahra M, Neumann UP, Jacob D, et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc 2005 May; 37 (4): 1700-2
12. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002 Oct; 8 (10 Suppl. 1): S14-18
13. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients [erratum appears in Hepatology 2003 Feb; 37 (2): 489]. Hepatology 2002 Jul; 36 (1): 202-10
14. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004 Nov; 41 (5): 830-6
15. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000 Sep; 6 (5): 553-61
16. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996 Nov; 24 (5): 1041-6
17. Papatheodoridis GV, Davies S, Dhillon AP, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001 Aug 15; 72 (3): 412-8
18. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004 Oct; 10 (10): 1258-62
19. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006 Jan; 12 (1): 51-7
20. Selzner N, Girgrah N, Al Adawi I, et al. Genotype and choice of calcineurin inhibitor influence response to antiviral therapy in liver transplant recipients treated for recurrent HCV [abstract]. Hepatology 2006; 44 (4 Suppl. 1): A785
21. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006 Jul; 12 (7): 1067-76
22. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 Apr 27; 75 (8): 1396-9
23. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004 Nov 27; 78 (10): 1488-95
24. Langrehr JM, Neumann UP, Lang M, et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplantation Proc 2002 Aug; 34 (5): 1565-6
25. Llado L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006 Apr; 44 (4): 710-6
26. Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transplant Int 2005 Dec; 18 (12): 1336-45
27. Nair S, Loss GE, Cohen AJ, et al. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006 Feb 27; 81 (4): 620-2
28. Wietzke-Braun P, Braun F, Sattler B, et al. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol 2004 Aug 1; 10 (15): 2213-7
29. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995 Jan; 21 (1): 30-4
30. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002 Feb; 8 (2): 123-31
31. Hirose R. Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients. Liver Transpl 2002 Feb; 8 (2): 143-5
32. Neuhaus P, Clavien P-A, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002 Feb; 8 (2): 132-42
33. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002 Jan; 8 (1): 40-6
34. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001 May; 7 (5): 442-50
35. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003 Jul; 38 (1): 34-41
36. Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005 Jul; 11 (7): 750-9
37. Berenguer M. Live donor liver transplantation for hepatitis C: new data, old story. Liver Transpl 2006 Apr; 12 (4): 516-9
38. Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006 Apr; 12 (4): 560-5
39. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004 Sep; 40 (3): 699-707
40. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 2004 Oct; 10 (10): 1263-8
41. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003 Oct; 9 (10): 1028-35
42. Bozorgzadeh A, Jain A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus [erratum appears in Transplantation 2004 Jun 27; 77 (12): 1920]. Transplantation 2004 Apr 15; 77 (7): 1066-70
43. Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004 Mar; 10 (3): 340-6
44. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004 Oct; 10 (10): 1248-55
45. Ferrell LD, Wright TL, Roberts J, et al. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992 Oct; 16 (4): 865-76
46. Scheuer P, Lefkowitch J. Liver biopsy interpretation. 6th ed. London: WB Saunders, 2002
47. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992 Apr; 15 (4): 567-71
48. Thung SN, Shim KS, Shieh YS, et al. Hepatitis C in liver allografts. Arch Pathol Lab Med 1993 Feb; 117 (2): 145-9
49. Baiocchi L, Tisone G, Palmieri G, et al. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplanta-tion. Liver Transpl Surg 1998 Nov; 4 (6): 441-7
50. Gordon FD, Pomfret EA, Pomposelli JJ, et al. Severe steatosis as the initial histologic manifestation of recurrent hepatitis C genotype 3. Hum Pathol 2004 May; 35 (5): 636-8
51. Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology 1995 Apr; 26 (4): 297-309
52. Mueller AR, Platz KP, Berg T, et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. Transpl Proc 1997 Nov; 29 (7): 2843-5
53. Petrovic LM, Villamil FG, Vierling JM, et al. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg 1997 Jul; 3 (4): 398-406
54. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004 Oct; 10 (10): 1233-9
55. Neff GW, Shire N, Ruiz P, et al. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection. Transpl Proc 2005 Dec; 37 (10): 4397-402
56. Wiesner RH, Sorrell M, Villamil F, et al. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003 Nov; 9 (11): S1-9
57. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004 Oct; 10 (10): 1240-7
58. Carrion JA, Navasa M, Bosch J, et al. Transient elastography to evaluate the severity of hepatitis C recurrence after liver transplantation. J Hepatol 2006; 44 Suppl. 2: S37
59. Corradi F, Piscaglia F, Tame R, et al. Staging of hepatic fibrosis by liver elastometry (fibroscan) in recurrent HCV infection in liver transplant recipients. J Hepatol 2006; 44 Suppl. 2: S59
60. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon -2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002 Nov; 8 (11): 1000-6
61. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10 (7): 850-8
62. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995 Oct; 22 (4 Pt 1): 1084-9
63. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10 (7): 859-67
64. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005 Aug; 11 (8): 941-9
65. Eren R, Landstein D, Terkieltaub D, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006 Mar; 80 (6): 2654-64
66. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002 Apr; 8 (4): 350-5
67. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 Aug; 42 (2): 255-62
68. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003 Sep; 39 (3): 389-96
69. Martinez-Bauer E, Carrion JA, Ramirez S, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation. J Hepatol 2006; 44 Suppl. 2: S64
70. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003 Sep; 9 (9): 905-15
71. Zileri Dal Verme L, Ilyas JA, Merra G, et al. HCV treatment in patients with end stage liver disease awaiting liver transplantation. J Hepatol 2006; 44 Suppl. 2: S232
72. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998 Sep; 28 (3): 831-8
73. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998 Jan 15; 65 (1): 82-6
74. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001 Feb-Mar; 33 (1-2): 1355-7
75. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transpl 2005 Jan; 5 (1): 118-24
76. Reddy KR, Fried MW, Dickson RC, et al. Interferon alfa-2b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicenter, randomized trial [abstract no. A199]. Gastroenterology 2002, 122
77. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials [erratum appears in Hepatology 2005 Aug; 42 (2): 506]. Hepatology 2005 Feb; 41 (2): 289-98
78. Kuo A, Lan B, Feng S, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis c virus (HCV) infection [abstract]. Hepatology 2006; 44 (4 Suppl. 1): A3
79. Petrolati A, Lionetti R, Lenci I, et al. PEG-interferon a-2a (40kd) with or without ribavirin in the treatment of naive patients with recurrent hepatitis C after liver transplantation [abstract]. Hepatology 2005; 42 (4 Suppl. 1): A726
80. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transpl Proc 2005 Jun; 37 (5): 2207-8
81. Duvoux C, Samuel D, Pageaux G, et al. Multicenter randomized trial of HCV treatment with peginterferon-alpha 2a and ribavirin in liver transplant patients with established recurrent hepatitis C: interim analysis. J Hepatol 2006; 44 Suppl. 2: S3
82. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003 Mar; 124 (3): 642-50
83. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004 Feb; 10 (2): 199-207
84. Bizollon T, Ahmed SNS, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003 Feb; 52 (2): 283-7
85. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 2004 Apr; 40 (4): 669-74
86. Ghalib R, Levine C, Hollinger B, et al. Sustained viral response using PEG IFN ALFA-2B plus ribavirin in patients with recurrent heaptitis C after liver transplantation [abstract]. Hepatology 2006; 44 (4 Suppl. 1): A778
87. Picciotto F, Lanza A, De Luca M, et al. Pegylated-interferon alpha-2b plus ribavirin in the treatment of HCV reinfection after liver transplantation experience of a single centre [abstract]. J Hepatol 2005; 42 Suppl. 2: A140
88. Iacob S, Beckebaum S, Cicinnati V, et al. 580 Predictive factors of sustained virological and histological response after combination antiviral therapy in transplanted patients with recurrent hepatitis C. J Hepatol 2006; 44 Suppl. 2: S215
89. Martini S, Lavezzo B, Saettone S, et al. Pegylated interferon (PEG-IFN) alpha-2b + ribavirin (RB) in the treatment of postliver transplant (LT) recurrent hepatitis C [abstract]. J Hepatol 2005; 42 Suppl. 2: A131
90. Casanovas-Taltavull T, Llobet M, Casanova A, et al. Predictive factors of early and sustained viral response in patients with recurrent hepatitis C after liver transplantation treated with combined therapy (IFN-alpha and ribavirin) [abstract]. Hepatology 2005; 42 (4 Suppl. 1): A738
91. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006 Jul 15; 82 (1): 43-7
92. Burra P, Targhetta S, Pevere S, et al. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transpl Proc 2006 May; 38 (4): 1127-30
93. Biselli M, Andreone P, Gramenzi A, et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006 Jan; 38 (1): 27-32
94. Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transpl Proc 2005 Dec; 37 (10): 4403-5
95. Bahra M, Neumann P, Jacob D, et al. Long term results after therapy with egylated interferon alpha 2a in HCV positive liver transplant recipients [abstract]. Hepatology 2005; 42 (4 Suppl. 1): A742
96. Lilly L, Girgrah N, Al Alwan A, et al. On treatment virological response of 70% in 100 patients treated with combination antiviral therapy for recurrent HCV following liver transplantation [abstract]. Hepatology 2005; 42 (4 Suppl. 1): A744
97. Anonymous. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20 (1): 15-20
98. Petrolati A, Lionetti R, Donato F, et al. PEG interferon alfa-2a (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: preliminary report of a randomized study [abstract]. J Hepatol 2004; 40 Suppl. 1: A100
99. Chacko K, Sussman N, Vierling J, et al. Adherence to the 80/80/80 rule in treatment of HCV recurrence after OLT is strongly Associated with sustained virologic response (SVR) [abstract]. Hepatology 2006; 44 (4 Suppl. 1): A789
100. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998 Apr; 123 (8): 1587-92
101. Dumortier J, Ducos E, Scoazec JY, et al. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepatitis 2006 Aug; 13 (8): 538-43
102. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003 Apr; 9 (4): 348-53
103. Kwo P, Saxena R, Cummings O, et al. Intravenous interferon during the anhepatic phase of liver transplantation and prevention of recurrence of cholestatic HCV. Liver Transpl 2007. In press
104. Paterson DL, Gayowski T, Wannstedt CF, et al. Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis. Clin Transpl 2000 Feb; 14 (1): 48-54
105. Singh N, Gayowski T, Wagener MM, et al. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999 Jan 15; 67 (1): 69-72
106. Azoulay D, Linhares MM, Huguet E, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002 Dec; 236 (6): 713-21
107. Roayaie S, Schiano TD, Thung SN, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003 Dec; 38 (6): 1428-36
108. Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004 Dec; 10 (12): 1497-503
109. Burton JR, Sonnenberg A, Rosen HR. Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl 2004 Oct; 10 (10 Suppl. 2): S59-64
110. Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver Transpl 2002 Oct; 8 (10 Suppl. 1): S38-43
111. Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003 Aug; 38 (2): 460-9
112. Yao FY, Saab S, Bass NM, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004 Jan; 39 (1): 230-8
113. Llado L, Castellote J, Figueras J. Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation? J Hepatol 2005 Apr; 42 (4): 468-72
114. McCashland TM. Retransplantation for recurrent hepatitis C: positive aspects. Liver Transpl 2003; 9 (11): S67-72
115. Wall WJ, Khakhar A. Retransplantation for recurrent hepatitis C: the argument against. Liver Transpl 2003; 9 (11): S73-8
116. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005 Jul; 43 (1): 53-9